Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Serine/threonine-protein kinase mTOR | ||
| Ligand | BDBM50320094 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_635345 (CHEMBL1119658) | ||
| IC50 | 5.2±n/a nM | ||
| Citation |  Zhang, N; Ayral-Kaloustian, S; Anderson, JT; Nguyen, T; Das, S; Venkatesan, AM; Brooijmans, N; Lucas, J; Yu, K; Hollander, I; Mallon, R 5-ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-alpha and mTOR for the treatment of breast cancer. Bioorg Med Chem Lett20:3526-9 (2010) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Serine/threonine-protein kinase mTOR | |||
| Name: | Serine/threonine-protein kinase mTOR | ||
| Synonyms: | FK506-binding protein 12-rapamycin complex-associated protein 1 | FKBP12-rapamycin complex-associated protein | FRAP | FRAP 1 (mTOR) | FRAP1 | FRAP2 | MTOR | MTOR_HUMAN | Mammalian Target of Rapamycin (mTOR) | P42345 | RAFT1 | RAPT1 | Rapamycin and FKBP12 target 1 | Rapamycin target protein | Serine/threonine-protein kinase (mTOR) | mTORC2 | ||
| Type: | Rapamycin target protein | ||
| Mol. Mass.: | 288917.12 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | P42345 | ||
| Residue: | 2549 | ||
| Sequence: |
| ||
| BDBM50320094 | |||
| n/a | |||
| Name | BDBM50320094 | ||
| Synonyms: | 1-(2-((5-methoxy-2-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indol-3-yl)methylene)-3-oxo-2,3-dihydrobenzofuran-5-yl)-3-(pyridin-3-yl)urea | CHEMBL1082986 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C30H26N6O4 | ||
| Mol. Mass. | 534.5652 | ||
| SMILES | COc1ccc2[nH]c(c(\C=C3\Oc4ccc(NC(=O)Nc5cccnc5)cc4C3=O)c2c1)-c1c(C)nn(C)c1C |(-3.98,-22,;-3.98,-23.54,;-2.64,-24.31,;-2.64,-25.86,;-1.31,-26.62,;.03,-25.85,;1.49,-26.32,;2.4,-25.07,;1.49,-23.82,;2.09,-22.4,;1.32,-21.07,;1.95,-19.66,;.8,-18.64,;.8,-17.11,;-.53,-16.34,;-1.86,-17.12,;-3.2,-16.35,;-3.2,-14.81,;-1.87,-14.03,;-4.54,-14.04,;-4.55,-12.51,;-5.88,-11.76,;-5.9,-10.23,;-4.57,-9.45,;-3.24,-10.21,;-3.23,-11.74,;-1.85,-18.65,;-.53,-19.4,;-.21,-20.91,;-1.24,-22.06,;.02,-24.3,;-1.31,-23.54,;3.94,-25.07,;4.84,-26.32,;4.36,-27.78,;6.3,-25.85,;6.3,-24.3,;7.55,-23.39,;4.84,-23.82,;4.36,-22.36,)| | ||
| Structure | 
| ||